Sanofi: Vaccines R&D pipeline raises bar in RSV, influenza, meningitis, pneumococcal disease

 VaccinesInvestor Event

Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease

• Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030, fueled by an accelerated pace of innovation
• Intent to start at least 5 innovative Phase 3 vaccine programs by 2025

Paris, June 29, 2023. Today Sanofi is hosting a Vaccines Investor Event dedicated to its pipeline with key members of its leadership team. The event will highlight how Sanofi’s strategy is supported by vaccines R&D. Since 2019, reinvesting in key growth drivers and a renewed pipeline has positioned the company well as it moves at speed on the second phase of its Play to Win strategy.

https://www.biospace.com/article/releases/press-release-vaccines-r-and-d-pipeline-raises-the-bar-in-rsv-influenza-meningitis-and-pneumococcal-disease/